Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthal…
$0.41-6.16%
报价 2026-11-13
市值
$100.5M
EV
$123.7M
PE (TTM)
–
预期 PE (FY2027)
–
52 周区间距高点 -83.3%
$0.20$2.47
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| OTLKOutlook Therapeutics, Inc. | $100.5M | -6.2% | +173.6% | 195.6% | – | – | – | |
| IPSCCentury Therapeutics, Inc. | $299.6M | +1.2% | -95.7% | 0% | – | – | – | |
| SPRBSpruce Biosciences, Inc. | $124.5M | +1.0% | +2590.0% | 0% | – | – | – | |
| CUECue Biopharma, Inc. | $117.1M | -7.9% | -84.6% | 99.7% | – | – | – | |
| NRXPNRx Pharmaceuticals, Inc. | $94.8M | -3.9% | +800.8% | 32.7% | – | – | – | |
| EQEquillium, Inc. | $81.8M | -2.3% | +41.8% | 0% | – | – | – | |
| HOWLWerewolf Therapeutics, Inc. | $47.6M | +0.0% | +232.0% | 86.4% | – | – | – | |
| OSTXOS Therapies Incorporated | $34.9M | -0.7% | -84.7% | 0% | – | – | – | |
| MDCXMedicus Pharma Ltd. | $2.8M | +13.4% | – | 0% | – | – | – | |
| 同行中位数 | – | – | +41.8% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。